Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
